Rheumatoid Arthritis: Treatment Options and Stem Cell Research

What is rheumatoid arthritis?

Rheumatoid arthritis (RA) is a long-term autoimmune disease. The immune system attacks the synovium, the thin lining of the joints, causing inflammation, pain and swelling. Without effective treatment, this inflammation can erode cartilage and bone and deform joints. RA can also affect the lungs, eyes, blood vessels and heart. The NHS rheumatoid arthritis guide explains the condition in detail.

Symptoms

• Pain, swelling and warmth in several joints, often the small joints of the hands, wrists and feet
• Symmetrical pattern: both sides of the body affected
• Morning stiffness lasting more than 30 minutes, often hours
• Fatigue, low-grade fever and feeling unwell
• Firm lumps under the skin (rheumatoid nodules)
• Later, larger joints such as the knees, shoulders and hips may be involved

What causes rheumatoid arthritis?

The exact cause is unknown. A combination of factors is involved:

• Genetics, including certain HLA gene types
• Smoking, the strongest known lifestyle risk factor
• Sex: RA is more common in women
• Age: often starts between 30 and 60
• Obesity and possibly gum disease (periodontitis)

How is RA diagnosed?

Early diagnosis matters because treatment in the first months gives the best chance of preventing damage. A rheumatologist uses:

Test	What it shows
Rheumatoid factor (RF)	Antibody present in many, not all, people with RA
Anti-CCP antibodies	More specific for RA; linked to more aggressive disease
ESR and CRP	Levels of inflammation
Full blood count, liver and kidney tests	Baseline before medicines and safety monitoring
X-ray of hands and feet	Erosions and joint space loss
Ultrasound or MRI	Early synovitis and erosions not yet visible on X-ray

Disease activity is often tracked with a score such as DAS28. If you have blood tests, imaging and rheumatology letters, you can send your reports for a doctor review to discuss whether any additional program is sensible for you.

Standard treatment comes first

Modern RA treatment is effective for many people, and it is the foundation of care. Guidelines such as NICE NG100 recommend a “treat-to-target” approach.

1. Conventional DMARDs. Methotrexate is usually first-line, sometimes with sulfasalazine, leflunomide or hydroxychloroquine.
2. Short-term steroids. To control flares while DMARDs take effect.
3. Biologic DMARDs. TNF inhibitors, abatacept, tocilizumab, rituximab and others for disease not controlled by conventional DMARDs.
4. Targeted synthetic DMARDs. JAK inhibitors such as tofacitinib, baricitinib and upadacitinib.
5. Physiotherapy, occupational therapy and podiatry.
6. Joint injections for individual inflamed joints.
7. Surgery for damaged joints, such as knee or hip replacement.
8. Cardiovascular risk management, because RA raises heart disease risk.

Regenerative and cellular approaches: the evidence

Mesenchymal stem cells

Mesenchymal stromal cells (MSCs) can dampen immune responses in the laboratory. That is why researchers are testing stem cell therapy in autoimmune diseases including RA.

• Human studies so far are mostly phase 1 and 2 trials with small numbers of patients, often people whose disease did not respond to standard drugs.
• These trials generally report that intravenous MSC infusions are well tolerated in the short term. Some report lower disease activity scores, but many lack a placebo group, and effects may be temporary.
• Systematic reviews describe the evidence as promising but preliminary. There is no proof that MSCs prevent joint erosion or allow people to stop DMARDs.

PRP and exosomes

PRP therapy is studied mainly in osteoarthritis. In RA, injecting PRP into an actively inflamed joint is not standard. Exosome therapy is at a laboratory and early clinical research stage for autoimmune disease.

CAR-T and stem cell transplant

You may read about CAR-T cell therapy or autologous haematopoietic stem cell transplantation (HSCT) for severe autoimmune disease. These are intensive hospital treatments involving chemotherapy, studied in specialist research centres. They are different from MSC therapy and are not offered as part of an outpatient regenerative program.

Regulatory status

No stem cell therapy is approved for RA by the US FDA, the Australian TGA or the UK MHRA, which is why patients from the US, Australia and the UK sometimes look abroad. The FDA warns about unapproved stem cell therapies. Patients considering treatment abroad should look for clinical trial participation first via ClinicalTrials.gov.

Who may be a candidate, and who should not

May be considered:

• Confirmed RA under the care of a rheumatologist
• Disease that remains active or troublesome despite standard treatment
• Willingness to continue prescribed medication
• Up-to-date blood tests and no active infection

Not suitable:

• Anyone wanting to replace DMARDs or biologics with stem cells
• Active infection, including untreated tuberculosis or hepatitis
• Active cancer or recent cancer
• Pregnancy or breastfeeding
• Severe lung, heart or kidney complications that are not stable
• Very high-dose immunosuppression without specialist agreement

Risks

• Infusion reactions: fever, headache, chills
• Infection risk, especially with immunosuppressive medicines
• Blood clots (rare, reported with intravenous cell products)
• Unknown long-term effects
• Disease flare if regular medication is stopped (avoid this)

Cells are prepared in ISO 9001:2015-certified partner laboratories.

What a Bangkok program looks like

1. Send your reports. Recent blood tests (RF, anti-CCP, CRP/ESR, blood count, liver and kidney function), imaging and rheumatology letters.
2. Doctor review. An honest opinion, including when we think a program is not worth it.
3. Assessment in Bangkok. Examination and screening blood tests.
4. Treatment. Depending on the plan, this may include intravenous MSC infusion or targeted joint care.
5. Coordinated follow-up. We encourage you to share all records with your rheumatologist.

Read how it works for the step-by-step journey. If your main problem is a worn knee joint, see our knee osteoarthritis guide. Patients with overlapping autoimmune conditions may also read our lupus guide.

Aftercare

• Continue your prescribed RA medicines exactly as before
• Rest on the day of treatment; avoid strenuous exercise for a few days
• Watch for fever or signs of infection and seek care promptly
• Keep tracking joint counts, stiffness and blood markers with your rheumatologist
• Maintain exercise, stop smoking and look after heart health

Sources

• NHS: Rheumatoid arthritis
• NICE: Rheumatoid arthritis in adults: management (NG100)
• U.S. FDA: Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
• Systematic reviews of mesenchymal stem cell therapy in rheumatoid arthritis, indexed on PubMed